Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 16

1.

Interleukin-13 Activates Distinct Cellular Pathways Leading to Ductular Reaction, Steatosis, and Fibrosis.

Gieseck RL 3rd, Ramalingam TR, Hart KM, Vannella KM, Cantu DA, Lu WY, Ferreira-González S, Forbes SJ, Vallier L, Wynn TA.

Immunity. 2016 Jul 19;45(1):145-58. doi: 10.1016/j.immuni.2016.06.009. Epub 2016 Jul 12.

PMID:
27421703
2.

M1 polarization bias and subsequent nonalcoholic steatohepatitis progression is attenuated by nitric oxide donor DETA NONOate via inhibition of CYP2E1-induced oxidative stress in obese mice.

Seth RK, Das S, Pourhoseini S, Dattaroy D, Igwe S, Ray JB, Fan D, Michelotti GA, Diehl AM, Chatterjee S.

J Pharmacol Exp Ther. 2015 Jan;352(1):77-89. doi: 10.1124/jpet.114.218131. Epub 2014 Oct 27.

3.

Interleukins in chronic liver disease: lessons learned from experimental mouse models.

Hammerich L, Tacke F.

Clin Exp Gastroenterol. 2014 Sep 1;7:297-306. doi: 10.2147/CEG.S43737. eCollection 2014. Review.

4.

A pilot study of serum microRNAs panel as potential biomarkers for diagnosis of nonalcoholic fatty liver disease.

Tan Y, Ge G, Pan T, Wen D, Gan J.

PLoS One. 2014 Aug 20;9(8):e105192. doi: 10.1371/journal.pone.0105192. eCollection 2014.

5.

The types of hepatic myofibroblasts contributing to liver fibrosis of different etiologies.

Xu J, Liu X, Koyama Y, Wang P, Lan T, Kim IG, Kim IH, Ma HY, Kisseleva T.

Front Pharmacol. 2014 Jul 22;5:167. doi: 10.3389/fphar.2014.00167. eCollection 2014. Review.

6.

The insulin-like growth factor 2 (IGF2) mRNA-binding protein p62/IGF2BP2-2 as a promoter of NAFLD and HCC?

Simon Y, Kessler SM, Bohle RM, Haybaeck J, Kiemer AK.

Gut. 2014 May;63(5):861-3. doi: 10.1136/gutjnl-2013-305736. Epub 2013 Oct 30. No abstract available.

7.

Hepatocellular proliferation correlates with inflammatory cell and cytokine changes in a murine model of nonalchoholic fatty liver disease.

Vansaun MN, Mendonsa AM, Lee Gorden D.

PLoS One. 2013 Sep 9;8(9):e73054. doi: 10.1371/journal.pone.0073054. eCollection 2013.

8.

The benefits of restraint: a pivotal role for IL-13 in hepatic glucose homeostasis.

Machado MV, Yang Y, Diehl AM.

J Clin Invest. 2013 Jan;123(1):115-7. doi: 10.1172/JCI67238. Epub 2012 Dec 21.

9.

Host responses in tissue repair and fibrosis.

Duffield JS, Lupher M, Thannickal VJ, Wynn TA.

Annu Rev Pathol. 2013 Jan 24;8:241-76. doi: 10.1146/annurev-pathol-020712-163930. Epub 2012 Oct 22. Review.

10.

Mechanisms of fibrosis: therapeutic translation for fibrotic disease.

Wynn TA, Ramalingam TR.

Nat Med. 2012 Jul 6;18(7):1028-40. doi: 10.1038/nm.2807. Review.

11.

IL-13 Signaling in Liver Fibrogenesis.

Liu Y, Munker S, Müllenbach R, Weng HL.

Front Immunol. 2012 May 11;3:116. doi: 10.3389/fimmu.2012.00116. eCollection 2012.

12.

Accumulation of natural killer T cells in progressive nonalcoholic fatty liver disease.

Syn WK, Oo YH, Pereira TA, Karaca GF, Jung Y, Omenetti A, Witek RP, Choi SS, Guy CD, Fearing CM, Teaberry V, Pereira FE, Adams DH, Diehl AM.

Hepatology. 2010 Jun;51(6):1998-2007. doi: 10.1002/hep.23599.

13.

Role of host genetics in fibrosis.

Hold GL, Untiveros P, Saunders KA, El-Omar EM.

Fibrogenesis Tissue Repair. 2009 Dec 4;2(1):6. doi: 10.1186/1755-1536-2-6.

14.

Apoptosis and cytokines in non-alcoholic steatohepatitis.

Syn WK, Choi SS, Diehl AM.

Clin Liver Dis. 2009 Nov;13(4):565-80. doi: 10.1016/j.cld.2009.07.003.

15.

Old and rising stars in the lymphoid liver.

Selmi C, Podda M, Gershwin ME.

Semin Immunopathol. 2009 Sep;31(3):279-82. doi: 10.1007/s00281-009-0175-2. Epub 2009 Jul 15. No abstract available.

16.

Pulmonary fibrosis: pathogenesis, etiology and regulation.

Wilson MS, Wynn TA.

Mucosal Immunol. 2009 Mar;2(2):103-21. doi: 10.1038/mi.2008.85. Epub 2009 Jan 7. Review.

Items per page

Supplemental Content

Write to the Help Desk